<!doctype html><html class=no-js lang=en><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>ç§‘ç ”æ—¥æŠ¥ 2026-01-27 - ç”Ÿä¿¡æ™®æ‹‰æ–¯</title>
<script>(function(e,t){e[t]=e[t].replace("no-js","js")})(document.documentElement,"className")</script><meta name=description content><meta property="og:url" content="https://ixxmu.github.io/posts/dailyreports/2026-01-27/"><meta property="og:site_name" content="ç”Ÿä¿¡æ™®æ‹‰æ–¯"><meta property="og:title" content="ç§‘ç ”æ—¥æŠ¥ 2026-01-27"><meta property="og:description" content="ğŸ“… Daily Report - 2026-01-27 ä»Šæ—¥ç­›é€‰å‡º 35 æ¡å†…å®¹ï¼Œæ¥è‡ª 2 ä¸ªæ¥æº"><meta property="og:locale" content="zh_cn"><meta property="og:type" content="article"><meta property="article:section" content="posts"><meta property="article:published_time" content="2026-01-27T00:00:00+00:00"><meta property="article:modified_time" content="2026-01-27T00:00:00+00:00"><meta property="article:tag" content="Research"><meta property="article:tag" content="Daily"><meta property="article:tag" content="Week052026"><meta itemprop=name content="ç§‘ç ”æ—¥æŠ¥ 2026-01-27"><meta itemprop=description content="ğŸ“… Daily Report - 2026-01-27 ä»Šæ—¥ç­›é€‰å‡º 35 æ¡å†…å®¹ï¼Œæ¥è‡ª 2 ä¸ªæ¥æº"><meta itemprop=datePublished content="2026-01-27T00:00:00+00:00"><meta itemprop=dateModified content="2026-01-27T00:00:00+00:00"><meta itemprop=wordCount content="2057"><meta itemprop=keywords content="Research,Daily,Week052026"><meta name=twitter:card content="summary"><meta name=twitter:title content="ç§‘ç ”æ—¥æŠ¥ 2026-01-27"><meta name=twitter:description content="ğŸ“… Daily Report - 2026-01-27 ä»Šæ—¥ç­›é€‰å‡º 35 æ¡å†…å®¹ï¼Œæ¥è‡ª 2 ä¸ªæ¥æº"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=dns-prefetch href=//fonts.googleapis.com><link rel=dns-prefetch href=//fonts.gstatic.com><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,700"><link rel=stylesheet href=../../../css/style.css><link rel=stylesheet href=../../../css/custom.css><link rel="shortcut icon" href=../../../favicon.ico></head><body class=body><div class="container container--outer"><header class=header><div class="container header__container"><div class=logo><a class=logo__link href=../../../ title=ç”Ÿä¿¡æ™®æ‹‰æ–¯ rel=home><div class="logo__item logo__text"><div class=logo__title>ç”Ÿä¿¡æ™®æ‹‰æ–¯</div><div class=logo__tagline>è¿‘åå¹´æœ€å€¼å¾—ä¸Šæ‰‹çš„ç”Ÿç‰©åŒ»å­¦ç”Ÿä¿¡ä»£ç </div></div></a></div><nav class=menu><button class=menu__btn aria-haspopup=true aria-expanded=false tabindex=0>
<span class=menu__btn-title tabindex=-1>Menu</span></button><ul class=menu__list><li class=menu__item><a class=menu__link href=../../../posts/><span class=menu__text>æ–‡ç« </span></a></li><li class=menu__item><a class=menu__link href=../../../tags/><span class=menu__text>æ ‡ç­¾</span></a></li><li class=menu__item><a class=menu__link href=../../../about/><span class=menu__text>å…³äº</span></a></li></ul></nav></div></header><div class="wrapper flex"><div class=primary><main class=main role=main><article class=post><header class=post__header><meta name=referrer content="never"><h1 class=post__title>ç§‘ç ”æ—¥æŠ¥ 2026-01-27</h1><div class="post__meta meta"><div class="meta__item-datetime meta__item"><svg class="meta__icon icon icon-time" width="16" height="14" viewBox="0 0 30 28"><path d="M15 0a14 14 0 110 28 1 1 0 010-28m0 3a3 3 0 100 22 3 3 0 000-22m1 4h-2v8.4l6.8 4.4L22 18l-6-3.8z"/></svg><time class=meta__text datetime=2026-01-27T00:00:00Z>2026-01-27</time></div><div class="meta__item-categories meta__item"><svg class="meta__icon icon icon-category" width="16" height="16" viewBox="0 0 16 16"><path d="m7 2 1 2h8v11H0V2z"/></svg><span class=meta__text><a class=meta__link href=../../../categories/dailyreport/ rel=category>DailyReport</a></span></div><div class="meta__item-author meta__item"><svg class="meta__icon icon icon-author" width="16" height="16" viewBox="0 0 16 16"><path d="M8 1c2 0 3.5 2 3.5 4.5S10 9 10 9c3 1 4 2 4 6H2c0-4 1-5 4-6 0 0-1.5-1-1.5-3.5S6 1 8 1"/></svg><span class=meta__text>Bloger</span></div></div></header><div class="post__toc toc"><div class=toc__title>Page content</div><div class=toc__menu><nav id=TableOfContents><ul><li><a href=#-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</a><ul><li><a href=#-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</a></li><li><a href=#-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</a></li></ul></li><li><a href=#-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</a><ul><li></li></ul></li><li><a href=#-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</a></li><li><a href=#-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</a></li></ul></nav></div></div><div class="content post__content clearfix"><h1 id=-daily-report---2026-01-27>ğŸ“… Daily Report - 2026-01-27</h1><blockquote><p>ä»Šæ—¥ç­›é€‰å‡º <strong>35</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p></blockquote><div class=powered-by-top>Powered by <a href=https://kyplus.de>ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href=https://claude.ai>Claude</a></div><hr><h2 id=-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2><h3 id=-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
Smyd5ä»‹å¯¼IL-4è¡¨è§‚é—ä¼ è°ƒæ§å·¨å™¬ç»†èƒæŠ—åŸå‘ˆé€’ï¼Œé©±åŠ¨Tç»†èƒååŒæŠ—è‚¿ç˜¤ï¼› hemeè°ƒæ§CD8+ Tç»†èƒè¡°ç«­çš„è½¬å½•æ´»æ€§ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>è‚¿ç˜¤å…ç–«ï¼šè§£æè‚¿ç˜¤å¾®ç¯å¢ƒã€å·¨å™¬ç»†èƒä¸Tç»†èƒçš„ç›¸äº’ä½œç”¨ï¼Œä»¥åŠè¡¨è§‚é—ä¼ è°ƒæ§æœºåˆ¶ã€‚</li><li>ç–¾ç—…æœºåˆ¶ï¼šç ”ç©¶å°è‚ å’Œç»“è‚ åŒ–ç”Ÿæ€§Panethç»†èƒã€é¼»æ—çª¦é³çŠ¶ç»†èƒç™Œã€å¼¥æ¼«æ€§ä¸­çº¿èƒ¶è´¨ç˜¤ã€é˜¿å°”èŒ¨æµ·é»˜ç—…å°é¼ æ¨¡å‹ã€è´¥è¡€ç—‡æ€§å¿ƒè‚Œç—…ç­‰ç–¾ç—…çš„åˆ†å­åŸºç¡€ã€‚</li><li>ç»†èƒç”Ÿç‰©å­¦ï¼šæ¢ç´¢å¤–æ³Œä½“åŠ¨åŠ›å­¦ã€RORÎ³t+å…ˆå¤©å…ç–«ç»†èƒåˆ†åŒ–ã€CD8+ Tç»†èƒå¹²æ€§ç»´æŒã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>å¤šç»„å­¦æ•´åˆåˆ†æï¼ˆMulti-omic profilingï¼‰æ­ç¤ºå¤æ‚ç–¾ç—…çš„åˆ†å­å›¾è°±ã€‚</li><li>ç©ºé—´è½¬å½•ç»„å­¦ï¼ˆSpatial transcriptomicsï¼‰å’Œå•ç»†èƒæµ‹åºï¼ˆscRNA-seqï¼‰æä¾›é«˜åˆ†è¾¨ç‡çš„ç»†èƒå’Œç»„ç»‡ä¿¡æ¯ã€‚</li></ul><h3 id=-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
æ­ç¤ºäº†è‚ é“æ…¢æ€§ç‚ç—‡å‘å±•ä¸ºç»“ç›´è‚ ç™Œçš„æ½œåœ¨å…ç–«æœºåˆ¶ï¼Œä»¥åŠé˜¿å°”èŒ¨æµ·é»˜ç—…é€šè¿‡åˆ†å­å¼€å…³è¯±å¯¼ç¥ç»å…ƒâ€œè‡ªæˆ‘å‰ªæâ€ä»¥è‡´è®°å¿†ä¸§å¤±çš„æœºåˆ¶ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>è‚ é“ç‚ç—‡ä¸ç»“ç›´è‚ ç™Œå‘ç—…æœºåˆ¶</li><li>é˜¿å°”èŒ¨æµ·é»˜ç—…ç›¸å…³çš„ç¥ç»å…ƒè¿æ¥æŸä¼¤ä¸è®°å¿†ä¸¢å¤±</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>å‘ç°è‚ é“å…ç–«é“¾å¼ååº”åœ¨ç‚ç—‡æ€§è‚ ç—…å‘ç»“ç›´è‚ ç™Œè½¬åŒ–ä¸­çš„ä½œç”¨ã€‚</li><li>è¯†åˆ«å‡ºæ·€ç²‰æ ·Î²å’Œç‚ç—‡ä¿¡å·æ±‡èšçš„åŒä¸€åˆ†å­å¼€å…³ï¼Œå¯¼è‡´ç¥ç»å…ƒå‰ªæã€‚</li></ul><hr><h2 id=-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</h2><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§¬ æ•°æ®å‰æ²¿ (33æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å‰10æ¡>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4><p><strong>1.</strong> â­ <strong>GSE315361 Smyd5 ä»‹å¯¼ IL-4 è¡¨è§‚é—ä¼ æ§åˆ¶å·¨å™¬ç»†èƒæŠ—åŸå‘ˆé€’ï¼Œä»è€Œé©±åŠ¨ååŒ T ç»†èƒä»‹å¯¼çš„è‚¿ç˜¤æŠ‘åˆ¶ [RNA-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€T cellã€macrophageã€antigenã€RNA-seqã€epigenetic</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Buyun Dang ; Yuling Hong ; Qingxiang Gao ; Shih-Chin ChengSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusIL-4 is classically associated with â€œM2â€ macrophages considered tumor-immunosuppressive, yet marker-based labels poorly reflect macrophage function in tumors. Reports of a non-canonical, IL-4â€“imprinted macrophage state (M2inf) with trained-immunity features prompted us to test whether such imprinting contributes to antitumor immunity in vivo. Here we show that, in B16F10 melanoma, IL-4 programs macrophages through the lysine methyltransferase Smyd5 to deposit promoter-proximal H3K36me3, increase MHC class II, and potentiate T cell activation. Myeloid Il4ra deletion increased tumor burden and reduced MHC class II and intratumoral T cell activation, whereas co-transfer of IL-4â€“primed macrophages suppressed tumors and expanded activated CD4 and CD8 T cells. Antitumor benefit required adaptive lymphocytes and macrophage-intrinsic MHC class II, as Rag1 deficiency or macrophage Rfx5 deletion abrogated tumor suppression. These findings identify a non-canonical, IL-4â€“imprinted macrophage program that enables antigen presentation and cooperative T cell immunity in this tumor context.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315361">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> â­ <strong>GSE315255 Smyd5 ä»‹å¯¼ IL-4 è¡¨è§‚é—ä¼ æ§åˆ¶å·¨å™¬ç»†èƒæŠ—åŸå‘ˆé€’ï¼Œä»è€Œé©±åŠ¨ååŒ T ç»†èƒä»‹å¯¼çš„è‚¿ç˜¤æŠ‘åˆ¶ [scRNA-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€T cellã€macrophageã€antigenã€scRNAã€epigenetic</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Buyun Dang ; Yuling Hong ; Qingxiang Gao ; Shih-Chin ChengSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusIL-4 is classically associated with â€œM2â€ macrophages considered tumor-immunosuppressive, yet marker-based labels poorly reflect macrophage function in tumors. Reports of a non-canonical, IL-4â€“imprinted macrophage state (M2inf) with trained-immunity features prompted us to test whether such imprinting contributes to antitumor immunity in vivo. Here we show that, in B16F10 melanoma, IL-4 programs macrophages through the lysine methyltransferase Smyd5 to deposit promoter-proximal H3K36me3, increase MHC class II, and potentiate T cell activation. Myeloid Il4ra deletion increased tumor burden and reduced MHC class II and intratumoral T cell activation, whereas co-transfer of IL-4â€“primed macrophages suppressed tumors and expanded activated CD4 and CD8 T cells. Antitumor benefit required adaptive lymphocytes and macrophage-intrinsic MHC class II, as Rag1 deficiency or macrophage Rfx5 deletion abrogated tumor suppression. These findings identify a non-canonical, IL-4â€“imprinted macrophage program that enables antigen presentation and cooperative T cell immunity in this tumor context.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315255">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> â­ <strong>GSE315253 Smyd5 ä»‹å¯¼ IL-4 è¡¨è§‚é—ä¼ æ§åˆ¶å·¨å™¬ç»†èƒæŠ—åŸå‘ˆé€’ï¼Œä»è€Œé©±åŠ¨ååŒ T ç»†èƒä»‹å¯¼çš„è‚¿ç˜¤æŠ‘åˆ¶ [ATAC-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€T cellã€macrophageã€antigenã€ATAC-seqã€epigenetic</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Buyun Dang ; Yuling Hong ; Qingxiang Gao ; Shih-Chin ChengSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusIL-4 is classically associated with â€œM2â€ macrophages considered tumor-immunosuppressive, yet marker-based labels poorly reflect macrophage function in tumors. Reports of a non-canonical, IL-4â€“imprinted macrophage state (M2inf) with trained-immunity features prompted us to test whether such imprinting contributes to antitumor immunity in vivo. Here we show that, in B16F10 melanoma, IL-4 programs macrophages through the lysine methyltransferase Smyd5 to deposit promoter-proximal H3K36me3, increase MHC class II, and potentiate T cell activation. Myeloid Il4ra deletion increased tumor burden and reduced MHC class II and intratumoral T cell activation, whereas co-transfer of IL-4â€“primed macrophages suppressed tumors and expanded activated CD4 and CD8 T cells. Antitumor benefit required adaptive lymphocytes and macrophage-intrinsic MHC class II, as Rag1 deficiency or macrophage Rfx5 deletion abrogated tumor suppression. These findings identify a non-canonical, IL-4â€“imprinted macrophage program that enables antigen presentation and cooperative T cell immunity in this tumor context.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315253">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> â­ <strong>GSE315363 Smyd5 ä»‹å¯¼ IL-4 è¡¨è§‚é—ä¼ æ§åˆ¶å·¨å™¬ç»†èƒæŠ—åŸå‘ˆé€’ï¼Œä»è€Œé©±åŠ¨ååŒ T ç»†èƒä»‹å¯¼çš„è‚¿ç˜¤æŠ‘åˆ¶ [Crispr ç­›é€‰]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€T cellã€macrophageã€antigenã€epigenetic</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Buyun Dang ; Yuling Hong ; Qingxiang Gao ; Shih-Chin ChengSeries Type : OtherOrganism : Mus musculusIL-4 is classically associated with â€œM2â€ macrophages considered tumor-immunosuppressive, yet marker-based labels poorly reflect macrophage function in tumors. Reports of a non-canonical, IL-4â€“imprinted macrophage state (M2inf) with trained-immunity features prompted us to test whether such imprinting contributes to antitumor immunity in vivo. Here we show that, in B16F10 melanoma, IL-4 programs macrophages through the lysine methyltransferase Smyd5 to deposit promoter-proximal H3K36me3, increase MHC class II, and potentiate T cell activation. Myeloid Il4ra deletion increased tumor burden and reduced MHC class II and intratumoral T cell activation, whereas co-transfer of IL-4â€“primed macrophages suppressed tumors and expanded activated CD4 and CD8 T cells. Antitumor benefit required adaptive lymphocytes and macrophage-intrinsic MHC class II, as Rag1 deficiency or macrophage Rfx5 deletion abrogated tumor suppression. These findings identify a non-canonical, IL-4â€“imprinted macrophage program that enables antigen presentation and cooperative T cell immunity in this tumor context.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315363">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> â­ <strong>GSE306374 å°è‚ å’Œç»“è‚ åŒ–ç”Ÿæ½˜æ°ç»†èƒçš„ç©ºé—´è½¬å½•ç»„å­¦é—ä¼ è°±</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€spatial transcriptomicsã€transcriptomicsã€regex:intestin(e|al)</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Tomohiro Muto ; Go ItoSeries Type : OtherOrganism : Homo sapiensMetaplasia is an epithelial alteration that appears in chronic inflammatory diseases. In ulcerative colitis, Paneth cell metaplasia (PCM) is a well-recognized feature, but its role in the inflamed epithelium remains unclear. Using spatial transcriptomics, we characterized the gene expression profile of PCM, elucidated its regulatory mechanisms, and clarified its functional role in the inflamed colonic epithelium.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306374">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> â­ <strong>GSE298564 å¤šç»„å­¦åˆ†ææ­ç¤ºé¼»çª¦é³çŠ¶ç»†èƒç™Œçš„åˆ†å­å›¾è°±å’Œå¼‚è´¨æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ [RPMI 2650 æ‰¹é‡ ATAC-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€carcinomaã€tumor microenvironmentã€ATAC-seq</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Chaelin You ; Junho Noh ; Jiheui Kim ; Kyuho KangSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensSinonasal squamous cell carcinoma (SNSCC) is a rare and aggressive malignancy with limited treatment options. Here, we conduct a comprehensive multi-omic analysis, integrating bulk and single-cell transcriptomics, epigenomics, and DNA methylation profiling. Our study identifies distinct gene signatures, cellular compositions, and regulatory mechanisms that drive SNSCC pathogenesis. Epigenetic alterations reveal a regulatory landscape underlying transcriptional changes, and we characterize heterogeneous tumor cell populations with unique molecular profiles. Hypoxia-related cells emerge as key drivers of angiogenesis and disease progression. Notably, we uncover a critical interaction between hypoxic tumor cells and endothelial tip cells, mediated by factors such as adrenomedullin (ADM), highlighting a pivotal mechanism in tumor development. These findings provide valuable insights into the tumor microenvironment (TME) of SNSCC and suggest potential therapeutic targets to improve treatment strategies for this challenging malignancy.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298564">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> â­ <strong>GSE298563 å¤šç»„å­¦åˆ†ææ­ç¤ºé¼»çª¦é³çŠ¶ç»†èƒç™Œçš„åˆ†å­å›¾è°±å’Œå¼‚è´¨æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ [RPMI2650 æ‰¹é‡ RNA-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€carcinomaã€tumor microenvironmentã€RNA-seq</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Chaelin You ; Junho Noh ; Jiheui Kim ; Kyuho KangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensSinonasal squamous cell carcinoma (SNSCC) is a rare and aggressive malignancy with limited treatment options. Here, we conduct a comprehensive multi-omic analysis, integrating bulk and single-cell transcriptomics, epigenomics, and DNA methylation profiling. Our study identifies distinct gene signatures, cellular compositions, and regulatory mechanisms that drive SNSCC pathogenesis. Epigenetic alterations reveal a regulatory landscape underlying transcriptional changes, and we characterize heterogeneous tumor cell populations with unique molecular profiles. Hypoxia-related cells emerge as key drivers of angiogenesis and disease progression. Notably, we uncover a critical interaction between hypoxic tumor cells and endothelial tip cells, mediated by factors such as adrenomedullin (ADM), highlighting a pivotal mechanism in tumor development. These findings provide valuable insights into the tumor microenvironment (TME) of SNSCC and suggest potential therapeutic targets to improve treatment strategies for this challenging malignancy.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298563">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>8.</strong> â­ <strong>GSE278145 å¤šç»„å­¦åˆ†ææ­ç¤ºé¼»çª¦é³çŠ¶ç»†èƒç™Œçš„åˆ†å­å›¾è°±å’Œå¼‚è´¨æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ [æ‰¹é‡ RNA æµ‹åº]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€carcinomaã€tumor microenvironmentã€RNA-seq</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Chaelin You ; Jihwan Park ; Keunsoo Kang ; Jaewoo Park ; Jungyeon Jang ; Myeongsang Yu ; Yoosam Chung ; Jiheui Kim ; Kyuho KangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensSinonasal squamous cell carcinoma (SNSCC) is a rare and aggressive malignancy with limited treatment options. Here, we conduct a comprehensive multi-omic analysis, integrating bulk and single-cell transcriptomics, epigenomics, and DNA methylation profiling. Our study identifies distinct gene signatures, cellular compositions, and regulatory mechanisms that drive SNSCC pathogenesis. Epigenetic alterations reveal a regulatory landscape underlying transcriptional changes, and we characterize heterogeneous tumor cell populations with unique molecular profiles. Hypoxia-related cells emerge as key drivers of angiogenesis and disease progression. Notably, we uncover a critical interaction between hypoxic tumor cells and endothelial tip cells, mediated by factors such as adrenomedullin (ADM), highlighting a pivotal mechanism in tumor development. These findings provide valuable insights into the tumor microenvironment (TME) of SNSCC and suggest potential therapeutic targets to improve treatment strategies for this challenging malignancy.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278145">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>9.</strong> â­ <strong>GSE278138 å¤šç»„å­¦åˆ†ææ­ç¤ºé¼»çª¦é³çŠ¶ç»†èƒç™Œçš„åˆ†å­å›¾è°±å’Œå¼‚è´¨æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ[DNAç”²åŸºåŒ–]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€carcinomaã€tumor microenvironmentã€methylation</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Chaelin You ; Jihwan Park ; Keunsoo Kang ; Jaewoo Park ; Jungyeon Jang ; Myeongsang Yu ; Yoosam Chung ; Jiheui Kim ; Kyuho KangSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensSinonasal squamous cell carcinoma (SNSCC) is a rare and aggressive malignancy with limited treatment options. Here, we conduct a comprehensive multi-omic analysis, integrating bulk and single-cell transcriptomics, epigenomics, and DNA methylation profiling. Our study identifies distinct gene signatures, cellular compositions, and regulatory mechanisms that drive SNSCC pathogenesis. Epigenetic alterations reveal a regulatory landscape underlying transcriptional changes, and we characterize heterogeneous tumor cell populations with unique molecular profiles. Hypoxia-related cells emerge as key drivers of angiogenesis and disease progression. Notably, we uncover a critical interaction between hypoxic tumor cells and endothelial tip cells, mediated by factors such as adrenomedullin (ADM), highlighting a pivotal mechanism in tumor development. These findings provide valuable insights into the tumor microenvironment (TME) of SNSCC and suggest potential therapeutic targets to improve treatment strategies for this challenging malignancy.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278138">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>10.</strong> â­ <strong>GSE288091 å¯¹ç» SOT101 å¤„ç†çš„ TC-1 å’Œ TRAMP-C å°é¼ çš„è‚¿ç˜¤ã€è„¾è„ã€æ·‹å·´ç»“ä¸­çš„ RNA æ ·æœ¬è¿›è¡Œ Nanostring åˆ†æ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€lymphã€regex:lymph(o|atic)?</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Lenka P JelinkovaSeries Type : OtherOrganism : Mus musculusNanrilkefusp alfa (nanril; SOT101) is an interleukin (IL)-15 receptor Î²Î³ superagonist that stimulates natural killer (NK) and CD8+ T cells, thereby promoting an innate and adaptive anti-tumor inflammatory microenvironment in mouse tumor models either in monotherapy or combined with an anti-programmed cell death protein 1 (PD-1) antibody. In cynomolgus monkeys, a clinical schedule was identified, which translated into the design of a phase 1/1b clinical trial, AURELIO-03 (NCT04234113). In 51 patients with advanced/metastatic solid tumors, nanril increased the proportions of CD8+ T cells and NK cells in peripheral blood and tumors. It had a favorable safety profile when administered subcutaneously on days 1, 2, 8 and 9 of each 21-day cycle as monotherapy (0.25-15 Î¼g/kg) or combined (1.5-12 Î¼g/kg) with the anti-PD-1 pembrolizumab (200 mg). The most frequent treatment-emergent adverse events were pyrexia, injection site reactions and chills. Furthermore, early clinical efficacy was observed, including in immune checkpoint blockade-resistant/refractory patients.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288091">æŸ¥çœ‹åŸæ–‡</a></li></ul><blockquote><p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 23 æ¡å†…å®¹ï¼Œè¯¦è§ <a href=#%E6%9B%B4%E5%A4%9A-%E6%95%B0%E6%8D%AE%E5%89%8D%E6%B2%BF>æ–‡æœ«</a></p></blockquote></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§ª åšå®¢æ›´æ–° (2æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å…¨éƒ¨2æ¡>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨2æ¡ï¼‰</h4><p><strong>1.</strong> â­ <strong>ä¸ºä»€ä¹ˆæ…¢æ€§è‚ é“ç‚ç—‡ä¼šå‘å±•æˆç»“è‚ ç™Œ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€inflammationã€gutã€regex:gut(-?microbiome)?</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šA newly uncovered immune chain reaction in the gut may explain why people with inflammatory bowel disease face a much higher risk of colorectal cancer. Researchers found that a powerful inflammatory signal flips on specialized gut immune cells, which then call in waves of white blood cells from the bone marrow and rewire them in ways that help tumors grow. This process appears to damage DNA in the gut lining and create a tumor-friendly environment.</li><li>ğŸ”— <a href=https://www.sciencedaily.com/releases/2026/01/260125083401.htm>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> <strong>é˜¿å°”èŒ¨æµ·é»˜ç—…å¯èƒ½ä¼šæ¬ºéª—å¤§è„‘ï¼Œä½¿å…¶æŠ¹å»è‡ªèº«çš„è®°å¿†ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šAlzheimerâ€™s may destroy memory by flipping a single molecular switch that tells neurons to prune their own connections. Researchers found that both amyloid beta and inflammation converge on the same receptor, triggering synapse loss. Surprisingly, neurons arenâ€™t passive victimsâ€”they actively respond to these signals. Targeting this receptor could offer a new way to protect memory beyond current amyloid-focused drugs.</li><li>ğŸ”— <a href=https://www.sciencedaily.com/releases/2026/01/260125083413.htm>æŸ¥çœ‹åŸæ–‡</a></li></ul></div></details><h2 id=-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2><table><thead><tr><th>å…³é”®è¯</th><th>å‡ºç°æ¬¡æ•°</th></tr></thead><tbody><tr><td>tumor</td><td>11</td></tr><tr><td>RNA-seq</td><td>7</td></tr><tr><td>T cell</td><td>6</td></tr><tr><td>carcinoma</td><td>6</td></tr><tr><td>macrophage</td><td>6</td></tr><tr><td>tumor microenvironment</td><td>6</td></tr><tr><td>ATAC-seq</td><td>4</td></tr><tr><td>antigen</td><td>4</td></tr><tr><td>epigenetic</td><td>4</td></tr><tr><td>immune</td><td>3</td></tr><tr><td>cancer</td><td>3</td></tr><tr><td>sequencing</td><td>2</td></tr><tr><td>Alzheimer</td><td>2</td></tr><tr><td>spatial</td><td>2</td></tr><tr><td>transcriptomics</td><td>2</td></tr><tr><td>single-cell</td><td>1</td></tr><tr><td>lymph</td><td>1</td></tr><tr><td>regex:lymph(o</td><td>atic)?</td></tr><tr><td>Visium</td><td>1</td></tr><tr><td>metabolic</td><td>1</td></tr></tbody></table><hr><h2 id=-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</h2><details><summary><a name=æ›´å¤š-æ•°æ®å‰æ²¿></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (23æ¡)</summary><div class=details-content markdown=1><ul><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280209">GSE280209 VAMP7ä¾èµ–çš„å†…è´¨ç½‘å’Œçº¿ç²’ä½“è›‹ç™½çš„æ™šæœŸå†…ä½“åˆ†æ³Œå½±å“è‚¿ç˜¤å¾®ç¯å¢ƒå’Œå·¨å™¬ç»†èƒçš„å‚ä¸</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277797">GSE277797 å¤šç»„å­¦åˆ†ææ­ç¤ºé¼»çª¦é³çŠ¶ç»†èƒç™Œçš„åˆ†å­å›¾è°±å’Œå¼‚è´¨æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ [snMultiome-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312103">GSE312103 RNA-seq æ­ç¤ºå¤–æºæ€§è¡€çº¢ç´ æ²»ç–—åŠ é€Ÿ CD8+ T ç»†èƒè€—ç«­</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312102">GSE312102 ATAC-seq æ­ç¤ºè¡€çº¢ç´ è°ƒèŠ‚é©±åŠ¨ CD8âº T ç»†èƒè€—ç«­çš„è½¬å½•å› å­çš„è½¬å½•æ´»æ€§</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312100">GSE312100 å•ç»†èƒ RNA æµ‹åºæ­ç¤ºï¼Œå…·æœ‰éæ´»æ€§è¡€çº¢ç´ ç»“åˆä½ç‚¹çš„ Bach2 ç»´æŒ CD8+ T ç»†èƒçš„å¹²æ€§</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263465">GSE263465 çŒªèƒŒæ ¹ç¥ç»èŠ‚ç¥ç»å…ƒçš„ç©ºé—´è½¬å½•ç»„åˆ†å­ç‰¹å¾[Visium]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317235">GSE317235 SAGA/ATACå¤åˆç‰©ç»´æŒå¼¥æ¼«æ€§ä¸­çº¿èƒ¶è´¨ç˜¤ä¸­å¼‚å¸¸çš„æŸ“è‰²è´¨è°ƒæ§å’Œä»£è°¢ç¨‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311597">GSE311597 åˆ†å±‚ Rorc(Î³t) é¡ºå¼è°ƒæ§çº§è”åè°ƒ RORÎ³tâº å…ˆå¤©å…ç–«ç»†èƒçš„åˆ†åŒ– [ChIP-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311595">GSE311595 åˆ†å±‚ Rorc(Î³t) é¡ºå¼è°ƒæ§çº§è”åè°ƒ RORÎ³tâº å…ˆå¤©å…ç–«ç»†èƒçš„åˆ†åŒ– [ATAC-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302249">GSE302249 è‚ºç™Œä¸­è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒçŠ¶æ€ä¸éä¿å®ˆæ€§lncRNAçš„å…³è”</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304308">GSE304308 é˜¿å°”èŒ¨æµ·é»˜ç—…å°é¼ çš„è„‘è„‚è´¨è°±å’Œå°‘çªèƒ¶è´¨ç»†èƒåŸºå› è¡¨è¾¾å¯¹é«˜è„‚é¥®é£Ÿçš„ååº”ä¸ä¸€è‡´ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317178">GSE317178 çº³ç±³è§å…‰ç´ é…¶-CD63æ ‡è®°æ­ç¤ºäº†å°é¼ å¯¼ç®¡åŸä½ç™Œå¯¼ç®¡å†…æ¨¡å‹ä¸­ç»†èƒå¤–å›Šæ³¡çš„åŠ¨åŠ›å­¦</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317110">GSE317110 åˆ©ç”¨16S rRNAæµ‹åºå¯¹å¤§é¼ ç²ªä¾¿æ ·æœ¬ä¸­çš„å¯¹ç…§ç»„ã€æ”¾å°„æ€§è‚ ç‚æ¨¡å‹ç»„å’Œæ²»ç–—ç»„è¿›è¡Œå¾®ç”Ÿç‰©ç»„åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317084">GSE317084 å¼‚æ¶å”‘è‹¯å’ŒPEP3è”åˆå¤„ç†åæ‹Ÿå—èŠ¥å¹¼è‹—çš„è½¬å½•ç»„åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316845">GSE316845 RNA-Seqç»“æœï¼Œæ¥è‡ªå‡æ‰‹æœ¯ç»„ã€è„“æ¯’ç—‡è¯±å¯¼å¿ƒè‚Œç—…ç»„å’ŒAAV-GATA4ç»„å°é¼ çš„å¿ƒè„</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315074">GSE315074 äººç±»å•æ ¸ç»†èƒæ¥æºçš„å·¨å™¬ç»†èƒä¸­è¿‡è¡¨è¾¾TRIM21ã€NFATc3æˆ–ASK1çš„å·®å¼‚è¡¨è¾¾åŸºå› </a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313641">GSE313641 RNA-seq åˆ†æéª¨è†œè›‹ç™½åˆºæ¿€çš„äººé¼»ä¸Šçš®ç»†èƒ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311856">GSE311856 å¯¹ MHC I ç±»åˆ†å­ä¼´ä¾£ tapasin çš„ä¸€ç§å˜ä½“ tapasin è¿›è¡Œæ·±åº¦çªå˜æ‰«æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311596">GSE311596 åˆ†å±‚ Rorc(Î³t) é¡ºå¼è°ƒæ§çº§è”åè°ƒ RORÎ³tâº å…ˆå¤©å…ç–«ç»†èƒçš„åˆ†åŒ– [ChIL-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309067">GSE309067 ç»†èƒç‰¹å¼‚æ€§è½¬å½•ç»„å­¦å’ŒåŸºå› æ²‰é»˜æ­ç¤ºæ°´é€šé“è›‹ç™½åœ¨ç¦¾æœ¬ç§‘æ¤ç‰©æ°”å­”è¿åŠ¨ä¸­çš„åŠŸèƒ½</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293843">GSE293843 è¯ç‰©æˆ–åŸºå›  PIKFYVE æŠ‘åˆ¶å¯¹ GEP-NET çš„å½±å“ [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE254518">GSE254518 DNAJB1è¡¨è¾¾é™ä½å¯¼è‡´é»‘è´¨è¡°è€ï¼šæ¥è‡ªå•æ ¸RNAæµ‹åºçš„å¯ç¤º</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE223837">GSE223837 SOX6è¯±å¯¼çš„ç»†èƒè¡°è€ä¸è¡°è€ç»†èƒæ¸…é™¤ç–—æ³•çš„è”åˆåº”ç”¨å¯æé«˜å®«é¢ˆç™Œçš„åŒ–ç–—æ•æ„Ÿæ€§</a></li></ul></div></details><hr><p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-01-26 21:43</em><br><em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p></div><footer class=post__footer><div class="post__tags tags clearfix"><svg class="tags__badge icon icon-tag" width="16" height="16" viewBox="0 0 32 32"><path d="M4 0h8s2 0 4 2l15 15s2 2 0 4L21 31s-2 2-4 0L2 16s-2-2-2-4V3s0-3 4-3m3 10a3 3 0 000-6 3 3 0 000 6"/></svg><ul class=tags__list><li class=tags__item><a class="tags__link btn" href=../../../tags/research/ rel=tag>Research</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/daily/ rel=tag>Daily</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/week052026/ rel=tag>Week052026</a></li></ul></div></footer></article></main><div class="authorbox clearfix"><div class=authorbox__header><span class=authorbox__name>About Bloger</span></div></div><nav class="pager flex"><div class="pager__item pager__item--prev"><a class=pager__link href=../../../posts/dailyreports/2026-01-26/ rel=prev><span class=pager__subtitle>Â«&#8201;Previous</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2026-01-26</p></a></div><div class="pager__item pager__item--next"><a class=pager__link href=../../../posts/dailyreports/2026-01-28/ rel=next><span class=pager__subtitle>Next&#8201;Â»</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2026-01-28</p></a></div></nav><section class=comments><div id=disqus_thread></div><script>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//kkitown.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></section></div><aside class=sidebar><div class="widget-search widget"><form class=widget-search__form role=search method=get action=https://google.com/search><input class=widget-search__field type=search placeholder=Searchâ€¦ name=q aria-label=Searchâ€¦>
<input class=widget-search__submit type=submit value=Search>
<input type=hidden name=sitesearch value=https://ixxmu.github.io/></form></div><div class="widget-recent widget"><h4 class=widget__title>Recent Posts</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-19/>ç§‘ç ”æ—¥æŠ¥ 2026-02-19</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-18/>ç§‘ç ”æ—¥æŠ¥ 2026-02-18</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-17/>ç§‘ç ”æ—¥æŠ¥ 2026-02-17</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-16/>ç§‘ç ”æ—¥æŠ¥ 2026-02-16</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-15/>ç§‘ç ”æ—¥æŠ¥ 2026-02-15</a></li></ul></div></div><div class="widget-categories widget"><h4 class=widget__title>Categories</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../categories/dailyreport/>DailyReport</a></li><li class=widget__item><a class=widget__link href=../../../categories/learnr/>LearnR</a></li></ul></div></div><div class="widget-taglist widget"><h4 class=widget__title>Tags</h4><div class=widget__content><a class="widget-taglist__link widget__link btn" href=../../../tags/daily/ title=Daily>Daily (112)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/research/ title=Research>Research (112)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week022026/ title=Week022026>Week022026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week032026/ title=Week032026>Week032026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week042026/ title=Week042026>Week042026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week052026/ title=Week052026>Week052026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week062026/ title=Week062026>Week062026 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week072026/ title=Week072026>Week072026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week452025/ title=Week452025>Week452025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week462025/ title=Week462025>Week462025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week472025/ title=Week472025>Week472025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week482025/ title=Week482025>Week482025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week492025/ title=Week492025>Week492025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week502025/ title=Week502025>Week502025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week512025/ title=Week512025>Week512025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week522025/ title=Week522025>Week522025 (7)</a></div><a href=../../../tags/></a></div><div class="widget-social widget"><h4 class="widget-social__title widget__title">Social</h4><div class="widget-social__content widget__content"><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Facebook rel="noopener noreferrer" href=https://facebook.com/username target=_blank><svg class="widget-social__link-icon icon icon-facebook" width="24" height="24" viewBox="0 0 352 352"><path d="m0 32v288c0 17.5 14.5 32 32 32h288c17.5.0 32-14.5 32-32V32c0-17.5-14.5-32-32-32H32C14.5.0.0 14.5.0 32zm320 0v288h-83V212h41.5l6-48H237v-31c0-14 3.5-23.5 23.5-23.5h26V66c-4.4-.6-19.8-1.5-37.5-1.5-36.9.0-62 22.2-62 63.5v36h-42v48h42v108H32V32z"/></svg>
<span>Facebook</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Twitter rel="noopener noreferrer" href=https://twitter.com/username target=_blank><svg class="widget-social__link-icon icon icon-twitter" width="24" height="24" viewBox="0 0 384 312"><path d="m384 36.9c-14.1 6.3-29.3 10.5-45.2 12.4 16.3-9.7 28.8-25.2 34.6-43.6-15.2 9-32.1 15.6-50 19.1-14.4-15.2-34.9-24.8-57.5-24.8-43.5.0-78.8 35.3-78.8 78.8.0 6.2.7 12.2 2 17.9-65.5-3.3-123.5-34.6-162.4-82.3C20 26 16.1 39.6 16.1 54c0 27.3 13.9 51.4 35 65.6-12.9-.4-25.1-4-35.7-9.9v1c0 38.2 27.2 70 63.2 77.2-6.6 1.8-13.6 2.8-20.8 2.8-5.1.0-10-.5-14.8-1.4 10 31.3 39.1 54.1 73.6 54.7-27 21.1-60.9 33.7-97.8 33.7-6.4.0-12.6-.4-18.8-1.1C34.9 299 76.3 312 120.8 312c144.9.0 224.1-120 224.1-224.1.0-3.4-.1-6.8-.2-10.2 15.4-11.1 28.7-25 39.3-40.8z"/></svg>
<span>Twitter</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Instagram rel="noopener noreferrer" href=https://www.instagram.com/username target=_blank><svg class="widget-social__link-icon icon icon-instagram" width="24" height="24" viewBox="0 0 256 256"><circle cx="193" cy="59" r="15"/><path fill-rule="evenodd" d="M101 0h54c41 0 58.4 3.9 74.5 17C256.2 37.5 256 74.8 256 97.7v60c0 26.7.0 60.4-26.5 81.4-16 13.4-33.5 16.9-74.5 16.9h-54c-41 0-57.5-3.5-74.5-16.9C1 218.9.5 186.3.1 160.5L0 155V97.7c0-23-.2-60.2 26.5-80.7C45 2 60 0 101 0zm4.9 23h44.3c45.8.0 58.3 3.5 70.3 17.5 11.8 13.2 12 30.1 12.5 62.9V156c.2 20.8.3 45.8-12.5 59.5-12 14-24.5 17.5-70.3 17.5h-44.3c-45.9.0-57.3-3.5-70.4-17.5-12.2-13-12.3-36.5-12.4-56.7v-55.6c.4-32.6.7-49.6 12.4-62.7C48 26.5 60 23 105.9 23zm19.6 144.5a42 42 0 100-84 42 42 0 000 84zm0 22.5a64.5 64.5.0 100-129 64.5 64.5.0 000 129z"/></svg>
<span>Instagram</span></a></div></div></div></aside></div><footer class=footer><div class="container footer__container flex"><div class=footer__copyright>&copy; 2026 ç”Ÿä¿¡æ™®æ‹‰æ–¯.
<span class=footer__copyright-credits>Generated with <a href=https://gohugo.io/ rel="nofollow noopener" target=_blank>Hugo</a> and <a href=https://github.com/Vimux/Mainroad/ rel="nofollow noopener" target=_blank>Mainroad</a> theme.</span></div></div></footer></div><script async defer src=../../../js/menu.js></script><script src=../../../js/custom.js></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.6/MathJax.js?config=TeX-AMS-MML_HTMLorMML" async></script></body></html>